R
Last Price
52 Week Range
CA$0.01 - CA$0.04
Next Earnings Date
Oct 27 2025 (Estimate)
Next Earnings Date
Oct 27 2025 (Est.)
Last Price
Market Cap | CA$8.63M |
EV | CA$8.65M |
Shares Outstanding | 431.32M |
Beta | 1.20 |
Analyst Rating | NOT_AVAILABLE |
Analyst Target Price | - |
P/E 2015E | - |
P/Revenue 2015E | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2015E | - |
Net Profit Margin 2015E | - |
ROE 2015E | - |
ROCE 2014 | -127.12% |
DPS 2015E | - |
Payout Ratio 2015E | - |
Div. Yield 2015E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
R
Revive Therapeutics Ltd.
RVV
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Frank, Michael
Employees
2
Website
revivethera.comIPO Date
2013-07-12
Headquarters
The Canadian Venture Building, 82 Richmond Street East, Toronto, Ontario, M5C 1P1, Canada
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.